137 related articles for article (PubMed ID: 37163598)
1. Cell survival pathways targeted in rare lung disease affecting women.
Yang B; Moss J
Sci Adv; 2023 May; 9(19):eadi1215. PubMed ID: 37163598
[TBL] [Abstract][Full Text] [Related]
2. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
[TBL] [Abstract][Full Text] [Related]
3. SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.
Hecimovic A; Jakopovic M; Pavlisa G; Jankovic M; Vukic-Dugac A; Redzepi G; Brcic L; Samarzija M; Gupta N
Lymphology; 2015 Jun; 48(2):97-102. PubMed ID: 26714374
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-beta 1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis.
Evans SE; Colby TV; Ryu JH; Limper AH
Chest; 2004 Mar; 125(3):1063-70. PubMed ID: 15006970
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.
Atochina-Vasserman EN; Abramova E; James ML; Rue R; Liu AY; Ersumo NT; Guo CJ; Gow AJ; Krymskaya VP
Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(12):L1447-54. PubMed ID: 26432869
[TBL] [Abstract][Full Text] [Related]
6. Lymphangioleiomyomatosis treatment with sirolimus.
Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
[TBL] [Abstract][Full Text] [Related]
7. Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response.
Miller S; Stewart ID; Clements D; Soomro I; Babaei-Jadidi R; Johnson SR
J Pathol Clin Res; 2020 Jul; 6(3):215-226. PubMed ID: 32352655
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis.
Huang YL; Chen PR; Lai YJ; Hsu HH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445268
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin K in Lymphangioleiomyomatosis: LAM Cell-Fibroblast Interactions Enhance Protease Activity by Extracellular Acidification.
Dongre A; Clements D; Fisher AJ; Johnson SR
Am J Pathol; 2017 Aug; 187(8):1750-1762. PubMed ID: 28623674
[TBL] [Abstract][Full Text] [Related]
10. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.
Glasgow CG; Steagall WK; Taveira-Dasilva A; Pacheco-Rodriguez G; Cai X; El-Chemaly S; Moses M; Darling T; Moss J
Respir Med; 2010 Jul; 104 Suppl 1(Suppl 1):S45-58. PubMed ID: 20630348
[TBL] [Abstract][Full Text] [Related]
11. In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor.
Gao L; Yue MM; Davis J; Hyjek E; Schuger L
Virchows Arch; 2014 Apr; 464(4):495-503. PubMed ID: 24570392
[TBL] [Abstract][Full Text] [Related]
12. Lymphangioleiomyomatosis: Current understanding and potential treatments.
Moir LM
Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial dysfunction is a key determinant of the rare disease lymphangioleiomyomatosis and provides a novel therapeutic target.
Abdelwahab EMM; Pal S; Kvell K; Sarosi V; Bai P; Rue R; Krymskaya V; McPhail D; Porter A; Pongracz JE
Oncogene; 2019 Apr; 38(16):3093-3101. PubMed ID: 30573768
[TBL] [Abstract][Full Text] [Related]
14. Lymphangioleiomyomatosis - a wolf in sheep's clothing.
Henske EP; McCormack FX
J Clin Invest; 2012 Nov; 122(11):3807-16. PubMed ID: 23114603
[TBL] [Abstract][Full Text] [Related]
15. Durability of Sirolimus for Lymphangioleiomyomatosis.
Martirossian A; Shah S; Carrete L; Valle J; Valentine V
Am J Med Sci; 2017 Dec; 354(6):603-607. PubMed ID: 29208258
[TBL] [Abstract][Full Text] [Related]
16. Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis.
Sun Y; Zhang E; Lao T; Pereira AM; Li C; Xiong L; Morrison T; Haley KJ; Zhou X; Yu JJ
Horm Cancer; 2014 Oct; 5(5):284-98. PubMed ID: 25069840
[TBL] [Abstract][Full Text] [Related]
17. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.
Prizant H; Taya M; Lerman I; Light A; Sen A; Mitra S; Foster TH; Hammes SR
Endocr Relat Cancer; 2016 Apr; 23(4):265-80. PubMed ID: 26880751
[TBL] [Abstract][Full Text] [Related]
18. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
19. Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis.
Bottolo L; Miller S; Johnson SR
Thorax; 2020 Aug; 75(8):679-688. PubMed ID: 32467337
[TBL] [Abstract][Full Text] [Related]
20. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis.
Matsumoto Y; Horiba K; Usuki J; Chu SC; Ferrans VJ; Moss J
Am J Respir Cell Mol Biol; 1999 Sep; 21(3):327-36. PubMed ID: 10460750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
